Literature DB >> 1623518

Ras-induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation.

X Lu1, S H Park, T C Thompson, D P Lane.   

Abstract

Using a reconstituted mouse prostate organ, the effects on endogenous p53 expression of the ras oncogene or of the ras + myc oncogenes were investigated. In this system the ras gene alone causes mild hyperplasia, but the combination of ras and myc leads to the formation of carcinomas. Surprisingly, while p53 mutations were found in cells derived from the reconstituted organs containing ras alone, no such mutations were found in the ras + myc-transformed cells. Their growth, unlike that of the cells containing ras alone, was not inhibited by transfection with plasmids encoding wild-type human p53. We suggest that expression of both activated ras and myc genes bypasses the need for p53 mutation by neutralizing the tumor suppressor activity of normal p53.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1623518     DOI: 10.1016/0092-8674(92)90541-j

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  35 in total

1.  Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding.

Authors:  E Shaulian; A Zauberman; D Ginsberg; M Oren
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

2.  Regulation of ES cell differentiation by functional and conformational modulation of p53.

Authors:  K Sabapathy; M Klemm; R Jaenisch; E F Wagner
Journal:  EMBO J       Date:  1997-10-15       Impact factor: 11.598

3.  p53 gene alterations and protein accumulation in colorectal cancer.

Authors:  R Bertorelle; G Esposito; C Belluco; L Bonaldi; A Del Mistro; D Nitti; M Lise; L Chieco-Bianchi
Journal:  Clin Mol Pathol       Date:  1996-04

4.  Use of genetic suppressor elements to dissect distinct biological effects of separate p53 domains.

Authors:  V S Ossovskaya; I A Mazo; M V Chernov; O B Chernova; Z Strezoska; R Kondratov; G R Stark; P M Chumakov; A V Gudkov
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

Review 5.  Role of p53 assessment in management of Barrett's esophagus.

Authors:  A K Kubba; N A Poole; A Watson
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

Review 6.  Cell cycle, CDKs and cancer: a changing paradigm.

Authors:  Marcos Malumbres; Mariano Barbacid
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

7.  Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy.

Authors:  Christel Devaud; Jennifer A Westwood; Liza B John; Jacqueline K Flynn; Sophie Paquet-Fifield; Connie P M Duong; Carmen S M Yong; Hollie J Pegram; Steven A Stacker; Marc G Achen; Trina J Stewart; Linda A Snyder; Michele W L Teng; Mark J Smyth; Phillip K Darcy; Michael H Kershaw
Journal:  Mol Ther       Date:  2013-09-19       Impact factor: 11.454

8.  Progression toward tumor cell phenotype is enhanced by overexpression of a mutant p53 tumor-suppressor gene isolated from nasopharyngeal carcinoma.

Authors:  Y Sun; K Nakamura; E Wendel; N Colburn
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

9.  Mutation of p53 in primary biopsy material and cell lines from Hodgkin disease.

Authors:  R K Gupta; K Patel; W F Bodmer; J G Bodmer
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

10.  The isolation of an RNA aptamer targeting to p53 protein with single amino acid mutation.

Authors:  Liang Chen; Farooq Rashid; Abdullah Shah; Hassaan M Awan; Mingming Wu; An Liu; Jun Wang; Tao Zhu; Zhaofeng Luo; Ge Shan
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.